Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Henry J. Breslin(Springhouse), Wei He(Hebei Medical University), Robert W. Kavash(Johnson & Johnson (United States)), Pamela J. Hornby(Springhouse), Craig J. Diamond(Janssen (United States)), Sui‐Po Zhang(Johnson & Johnson (United States)), Alexey B. Dyatkin(Janssen (United States)), Paul R. Wade(Janssen (United States)), Chaozhong Cai(Janssen (United States)), Tamara A. Miskowski(Janssen (United States))
Cited by 42
Related Papers
The pharmacology and therapeutic applications of monoclonal antibodies
|Pharmacology Research & Perspectives|2019|346
<i>C</i>-Glycosidation Technology With Free Radical Reactions
|Synlett|1998|151
Early-Onset Preeclampsia Is Associated With Gut Microbial Alterations in Antepartum and Postpartum Women
|Frontiers in Cellular and Infection Microbiology|2019|150
Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist
|British Journal of Pharmacology|2012|121
Alternative functional in vitro models of human intestinal epithelia
|Frontiers in Pharmacology|2013|108